Seroquel Trial Date Set

AstraZeneca PLC
12 March 2008



                TRIAL DATE SET FOR SEROQUEL(R) PATENT LITIGATION




LONDON 12 March 2008 - AstraZeneca PLC today announced a trial date has been set
for patent litigation in the US District Court for the District of New Jersey
against Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging
infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings
of Abbreviated New Drug Applications (ANDAs). The ANDAs seek approval to market
generic versions of SEROQUEL(R) (quetiapine fumarate tablets) in the US before
SEROQUEL's patent expires in 2011.  The Court has set a date for trial beginning
on 11 August 2008.



About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the
research, development, manufacturing and marketing of meaningful prescription
medicines and supplier for healthcare services. AstraZeneca is one of the
world's leading pharmaceutical companies with healthcare sales of $29.55 billion
and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory,
oncology and infectious disease medicines.  In the United States, AstraZeneca is
a $13.35 billion dollar healthcare business with 12,200 employees committed to
improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global) as well as the FTSE4Good Index.



For more information visit www.astrazeneca.com.



The statements contain herein include forward-looking statements.  Although we
believe our expectations are based on reasonable assumptions, any
forward-looking statements, by their very nature, involve risks and
uncertainties and may be influenced by factors that could cause actual outcomes
and results to be materially different from those predicted.  The
forward-looking statements reflect knowledge and information available at the
date of the preparation of this press release and the Company undertakes no
obligation to update these forward-looking statements.  Important factors that
could cause actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond our control, include,
among other things, those risk factors identified in the Company's Annual Report
and Form 20-F Information for 2007.  Nothing contained herein should be
construed as a profit forecast.



Media Enquiries:
Steve Brown [phone] (24 hours)
Chris Sampson [phone] (24 hours)
Neil McCrae [phone] (24 hours)

Investor Enquiries UK:
Jonathan Hunt [phone] mob: [phone]
Mina Blair [phone] mob: [phone]
Karl Hard [phone] mob: [phone]

Investor Enquiries US:
Ed Seage [phone] mob: [phone]
Jorgen Winroth [phone] mob: [phone]
Peter Vozzo (MedImmune) [phone] mob: [phone]






                                      ###






                      This information is provided by RNS
            The company news service from the London Stock Exchange